The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

That news sent the stocks of market leaders Novo Nordisk A/S (NVO) and Eli Lilly & Co. (LLY) higher, along with Viking Therapeutics Inc. (VKTX) For more, read: Weight-loss stocks get a boost from new ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

In the case of WW, analyst Linda Bolton Weiser assigned the stock a buy rating back in March, in a note framed around the question, "Why would an investor be interested in investing in WW, which ...